Works matching IS 01676997 AND DT 2021 AND VI 39 AND IP 5

Results: 30

Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1439, doi. 10.1007/s10637-021-01126-1

By:

Xiong, Chen;
Wang, Zhihuai;
Wang, Guifu;
Zhang, Chi;
Jin, Shengjie;
Jiang, Guoqing;
Bai, Dousheng

Publication type:

Article

Comment on "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma".

Published in:

2021

By:

Lin, Jiong

Publication type:

Letter

Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1267, doi. 10.1007/s10637-021-01123-4

By:

Meng, Fanyi;
Chen, Yinshuang;
Yang, Man;
Zhang, Hongjian;
Wang, Weipeng

Publication type:

Article

Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1436, doi. 10.1007/s10637-021-01122-5

By:

Zhang, Ming-jun;
Chen, Dong-sheng;
Li, Si;
Chen, Lin;
Qi, Ying-xue;
Zhang, Cong-jun

Publication type:

Article

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1357, doi. 10.1007/s10637-021-01119-0

By:

Thein, Kyaw Zin;
Piha-Paul, Sarina A.;
Tsimberidou, Apostolia;
Karp, Daniel D.;
Janku, Filip;
Zarifa, Abdulrazzak;
Shah, Jatin;
Milton, Denái R.;
Bean, Stacie;
McQuinn, Lacey;
Gong, Jing;
Colen, Rivka;
Carter, Brett W.;
Subbiah, Vivek;
Ogbonna, Deby C.;
Pant, Shubham;
Meric-Bernstam, Funda;
Naing, Aung

Publication type:

Article

Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1256, doi. 10.1007/s10637-021-01118-1

By:

Fujii, Yuki;
Kamachi, Hirofumi;
Matsuzawa, Fumihiko;
Mizukami, Tatsuzo;
Kobayashi, Nozomi;
Fukai, Moto;
Taketomi, Akinobu

Publication type:

Article

The drug lag issue: a 20-year review of China.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1389, doi. 10.1007/s10637-021-01117-2

By:

Li, Xiaoyu;
Yang, Yue

Publication type:

Article

Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1432, doi. 10.1007/s10637-021-01116-3

By:

Wang, Yong;
Xu, Jun;
Luo, Ningning;
Qi, Chuang;
Tao, Rongjie

Publication type:

Article

Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real‐world treatment outcomes.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1422, doi. 10.1007/s10637-021-01115-4

By:

Fukudo, Masahide;
Asai, Keiko;
Tani, Chikayoshi;
Miyamoto, Masashi;
Ando, Katsuyoshi;
Ueno, Nobuhiro

Publication type:

Article

First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1348, doi. 10.1007/s10637-021-01112-7

By:

Janku, Filip;
LoRusso, Patricia;
Mansfield, Aaron S.;
Nanda, Rita;
Spira, Alexander;
Wang, Tianli;
Melhem-Bertrandt, Amal;
Sugg, Jennifer;
Ball, Howard A.

Publication type:

Article

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1375, doi. 10.1007/s10637-021-01111-8

By:

Chan, Stephen L.;
Cheng, Paul N.M.;
Liu, Angela M.;
Chan, Landon L.;
Li, Leung;
Chu, Cheuk M.;
Chong, Charing C.N.;
Lau, Yat M.;
Yeo, Winnie;
Ng, Kelvin K.C.;
Yu, Simon C.H.;
Mok, Tony S.K.;
Chan, Anthony W.H.

Publication type:

Article

A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1335, doi. 10.1007/s10637-021-01110-9

By:

Jeong, Hyehyun;
Hong, Yong Sang;
Kim, Jeong Eun;
Lim, Hyeong-Seok;
Ahn, Joong Bae;
Shin, Sang Joon;
Park, Young Suk;
Kim, Seung Tae;
Han, Sae-Won;
Kim, Tae-You;
Kim, Tae Won

Publication type:

Article

Identification of novel inhibitors of GLUT1 by virtual screening and cell-based assays.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1242, doi. 10.1007/s10637-021-01109-2

By:

Chen, Xiaotong;
Zhao, Yunshuo;
Lyu, Sifan;
Gao, Guanfei;
Gao, Yanfeng;
Qi, Yuanming;
Du, Jiangfeng

Publication type:

Article

Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1419, doi. 10.1007/s10637-021-01108-3

By:

Jin, Lin-ling;
Wu, Zhen-zhen;
Wang, Yan-li;
Chen, Dong-sheng;
Li, Si;
Xiao, Mingzhe;
Zhao, Xin

Publication type:

Article

Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1232, doi. 10.1007/s10637-021-01106-5

By:

Abdullah, Nurul A;
Inman, Martyn;
Moody, Christopher J.;
Storr, Sarah J;
Martin, Stewart G

Publication type:

Article

Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1411, doi. 10.1007/s10637-021-01105-6

By:

Su, Hui;
Yu, Chao;
Ma, Xuezhen;
Song, Qingcui

Publication type:

Article

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1324, doi. 10.1007/s10637-021-01104-7

By:

Piha-Paul, Sarina A.;
Azaro, Analía;
Arkenau, Hendrik Tobias;
Oh, Do-Youn;
Galsky, Matthew D.;
Pal, Sumanta Kumar;
Hamada, Kensuke;
He, Yaohua;
Yamamiya, Ikuo;
Benhadji, Karim A;
Hollebecque, Antoine

Publication type:

Article

A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1222, doi. 10.1007/s10637-021-01102-9

By:

Xue, Jinbing;
Wu, Gang;
Ejaz, Umer;
Akhtar, Fahad;
Wan, Xinyu;
Zhu, Yong;
Geng, Aixing;
Chen, Yadong;
He, Shuying

Publication type:

Article

The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1383, doi. 10.1007/s10637-021-01101-w

By:

Yuan, Peng;
Wang, Fei;
Zhu, Guangyu;
Chen, Baoan

Publication type:

Article

Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1405, doi. 10.1007/s10637-021-01100-x

By:

Hahn, Andrew W.;
Chahoud, Jad;
Campbell, Matthew T.;
Karp, Daniel D.;
Wang, Jennifer;
Stephen, Bettzy;
Tu, Shi-Ming;
Pettaway, Curtis A.;
Naing, Aung

Publication type:

Article

Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1315, doi. 10.1007/s10637-021-01099-1

By:

Hou, Ming-Mo;
Ho, Ching-Liang;
Lin, Hsuan-Yu;
Zhu, Yunting;
Zhang, Xiaodi

Publication type:

Article

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1399, doi. 10.1007/s10637-021-01098-2

By:

Inoue, Hiroto;
Todaka, Akiko;
Yamazaki, Kentaro;
Fushiki, Kunihiro;
Shirasu, Hiromichi;
Kawakami, Takeshi;
Tsushima, Takahiro;
Hamauchi, Satoshi;
Yokota, Tomoya;
Machida, Nozomu;
Fukutomi, Akira;
Onozawa, Yusuke;
Andoh, Akira;
Yasui, Hirofumi

Publication type:

Article

Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1213, doi. 10.1007/s10637-021-01096-4

By:

Li, Meng-Zhu;
Meng, Tao;
Song, Shan-Shan;
Bao, Xu-Bin;
Ma, Lan-Ping;
Zhang, Ning;
Yu, Ting;
Zhang, Yong-Liang;
Xiong, Bing;
Shen, Jing-Kang;
Miao, Ze-Hong;
He, Jin-Xue

Publication type:

Article

Effect of severe renal impairment on the pharmacokinetics of brigatinib.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1306, doi. 10.1007/s10637-021-01095-5

By:

Gupta, Neeraj;
Hanley, Michael J.;
Kerstein, David;
Tugnait, Meera;
Narasimhan, Narayana;
Marbury, Thomas C.;
Venkatakrishnan, Karthik

Publication type:

Article

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1298, doi. 10.1007/s10637-021-01093-7

By:

Pedersen, Katrina S.;
Grierson, Patrick M.;
Picus, Joel;
Lockhart, A. Craig;
Roth, Bruce J.;
Liu, Jingxia;
Morton, Ashley;
Chan, Emily;
Huffman, Jesse;
Liang, Chris;
Wang-Gillam, Andrea;
Tan, Benjamin

Publication type:

Article

Author Correction to: Advances in anti-BRAF therapies for lung cancer.

Published in:

2021

By:

Roviello, Giandomenico;
D'Angelo, Alberto;
Sirico, Marianna;
Pittacolo, Matteo;
Conter, Felipe Umpierre;
Sobhani, Navid

Publication type:

Correction Notice

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1284, doi. 10.1007/s10637-021-01088-4

By:

Falchook, Gerald S.;
Peeters, Marc;
Rottey, Sylvie;
Dirix, Luc Y.;
Obermannova, Radka;
Cohen, Jonathan E.;
Perets, Ruth;
Frommer, Ronnie Shapira;
Bauer, Todd M.;
Wang, Judy S.;
Carvajal, Richard D.;
Sabari, Joshua;
Chapman, Sonya;
Zhang, Wei;
Calderon, Boris;
Peterson, Daniel A.

Publication type:

Article

Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1366, doi. 10.1007/s10637-021-01085-7

By:

Lee, Jii Bum;
Jung, Minkyu;
Beom, Seung Hoon;
Kim, Gun Min;
Kim, Hye Ryun;
Choi, Hye Jin;
Sohn, Joo Hyuk;
Ahn, Joong Bae;
Rha, Sun Young;
Chung, Hyun Cheol

Publication type:

Article

FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1201, doi. 10.1007/s10637-021-01061-1

By:

Song, Xiaoping;
Tang, Wei;
Peng, Hui;
Qi, Xin;
Li, Jing

Publication type:

Article

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1275, doi. 10.1007/s10637-020-01025-x

By:

Olmedo, María Eugenia;
Forster, Martin;
Moreno, Victor;
López-Criado, María Pilar;
Braña, Irene;
Flynn, Michael;
Doger, Bernard;
de Miguel, María;
López-Vilariño, José Antonio;
Núñez, Rafael;
Kahatt, Carmen;
Cullell-Young, Martin;
Zeaiter, Ali;
Calvo, Emiliano

Publication type:

Article